Литература
1. Дедов И.И., Шестакова М.В., Викулова О.К., Железнякова А.В. и др. Сахарный диабет в Российской Федерации: распространенность, заболеваемость, смертность, параметры углеводного обмена и структура сахароснижающей терапии по данным Федерального регистра сахарного диабета, статус 2017 г. // Сахарный диабет. 2018. Т. 21, № 3. С. 144-159.
2. Дедов И.И., Шестакова М.В., Галстян Г.Р. Распространенность сахарного диабета 2 типа у взрослого населения России (исследование NATION) // Сахарный диабет. 2016. Т. 19, № 2. С. 104-112.
3. Cruz-Jentoft A.J. et al. Sarcopenia: revised European consensus on definition and diagnosis // Age and Ageing. 2018. Oct 13.
4. Grimby G., Saltin B. The ageing muscle // Clin. Physiol. 1983. Vol. 3, N 3. Р. 209-218.
5. Kamimoto L.A. et al. Surveillance for five health risks among older adults - United States, 1993-1997 // MMWR CDC Surveill. Summ. 1999. Vol. 48, N 8. P. 89-130.
6. Kim T.N. et al. Prevalence and determinant factors of sarcopenia in patients with type 2 diabetes: the Korean Sarcopenic Obesity Study (KSOS) // Diabetes Care. 2010. Vol. 33, N 7. P. 1497-1499.
7. Мисникова И.В., Ковалева Ю.А. Климина Н.А., Полякова Е.Ю. Оценка мышечной и жировой массы у пациентов с сахарным диабетом 2-го типа по результатам двухэнергетической рентгеновской аб-сорбциометрии // Альманах клинической медицины. 2018. Т. 46, № 3. С. 222-232.
8. Гурьева И.В., Онучина Ю.С., Дымочка М.А., Щелыкалина С.П. и др. Особенности саркопении и состава тела на основании биоимпе-дансометрии у пациентов с сахарным диабетом 2 типа // Вопр. диетологии. 2017. Т. 7, № 3. С. 11-19.
9. Morley J.E. Diabetes, sarcopenia, and frailty // Clin. Geriatr. Med. 2008. Vol. 24, N 3. P. 455-469.
10. Roubenoff R. Sarcopenic obesity: the confluence of two epidemics // Obes. Res. 2004. Vol. 1. P. 887-888.
11. Мисникова И.В., Ковалева Ю.А., Климина Н.А. Саркопеническое ожирение // РМЖ. 2017. Т. 25, № 1. С. 24-29.
12. Baumgartner R.N. Body composition in healthy aging // Ann. N. Y. Acad. Sci. 2000. Vol. 904. P. 437-448.
13. Шостак Н.А., Мурадянц А.А., Кондрашов А.А. Саркопения и перекрестные синдромы - значение в клинической практике // Клиницист. 2016. Т. 10, № 3. С. 10-14.
14. Dalal M. et al. Elevated serum advanced glycation end products and poor grip strength in older community-dwelling women // J. Gerontol. A Biomed. Sci. Med. Sci. 2009. Vol. 64, N 1. P. 132-137.
15. Гурьева И.В., Онучина Ю.С. Современные подходы к определению, диагностике и классификации диабетической полинейропатии. Патогенетические аспекты лечения // Consilium Medicum. 2016. Т. 18, № 12. С. 103-109.
16. Casellini C., Vinik A. Clinical manifestations and current treatment options for diabetic neuropathies // Endocr. Pract. 2007. Vol. 13, N 5. P. 550-566.
17. Tesfaye S. et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments // Diabetes Care. 2010. Vol. 33, N 10. P. 2285-2293.
18. Vinik A.I. et aL Diabetic neuropathy in older adults // CLin. Geriatr. Med. 2008. VoL. 24, N 3. P. 407-435.
19. Andreassen C.S., Jakobsen J., Andersen H. Muscle weakness: a progressive late complication in diabetic distal symmetric polyneuropathy // Diabetes. 2006. VoL. 55, N 3. P. 806-812.
20. Остеопороз : руководство для врачей / под ред. О.М. Лесняк. М. : ГЭОТАР-Медиа, 2016.
21. Bus S.A. et aL. Intrinsic muscle atrophy and toe deformity in the diabetic neuropathic foot: a magnetic resonance imaging study // Diabetes Care. 2002. VoL. 25, N 8. P. 1444-1450.
22. PfLipsen M.C. et aL. The prevaLence of vitamin B12 deficiency in patients with type 2 diabetes: a cross-sectionaL study // J. Am. Board Fam. Med. 2009. VoL. 22, N 5. P. 528-534.
23. Fujita S. et aL. Effect of insuLin on human skeLetaL muscLe protein synthesis is moduLated by insuLin-induced changes in muscLe bLood flow and amino acid avaiLabiLity // Am. J. PhysioL. EndocrinoL. Metab. 2006. VoL. 291, N 4. P. E745-E754.
24. Nomura T. et aL. MuscLe strength is a marker of insuLin resistance in patients with type 2 diabetes: a piLot study // Endocr. J. 2007. VoL. 54, N 5. P. 791-796.
25. Kohn F.M. Testosterone and body functions // Aging MaLe. 2006. VoL. 9, N 4. P. 183-188.
26. Кравченко И.В., Фуралев В.А., Тихонов А.В. Титин, миомезин и миозин-связывающий белок С активируют синтез механо-ростового фактора в миобластах мыши // Соврем. пробл. науки и образования. 2012. № 6. C. 9.
27. Ундрицов И.М., Ундрицов В.М., Андреев Э.Ф. Миостатин - отрицательный регулятор мышечной массы - революция или сенсация? // Физкультура в профилактике, лечении и реабилитации. 2003. № 1. С. 64-69.
28. MorLey J.E., Baumgartner R.N. Cytokine-related aging process // J. Gerontol. A Biol. Sci. Med. Sci. 2004. Vol. 59, N 9. P. 924-929.
29. Cesari M. et al. Inflammatory markers and physical performance in older persons: the InCHIANTI study // J. Gerontol. A Biol. Sci. Med. Sci. 2004. Vol. 59, N 3. P. M242-M248.
30. Pereira R.A. Sarcopenia in chronic kidney disease on conservative therapy: prevalence and association with mortality // Nephrol. Dial. Transplant. 2015. Vol. 30, N 10. P. 1718-1725.
31. Perry H.M. et al. Longitudinal changes in serum 25-hydroxyvitamin D in older people // Metabolism. 1999. Vol. 48, N 8. P. 1028-1032.
32. Bischoff-Ferrari H.A., Borchers M., Gudat F., DurmuLLer U. et aL. Vitamin D receptor expression in human muscle tissue decreases with age // J. Bone Miner. Res. 2004. Vol. 19. Р. 265-269.
33. Bouillon R., Bischoff-Ferrari H., Willett W. Vitamin D and health: perspectives from mice and man // J. Bone Miner. Res. 2008. Vol. 23, N 7. P. 974-979.
34. De Boland A.R., Boland R.L. Non-genomic signal transduction pathway of vitamin D in muscle // Cell. Signal. 1994. Vol. 6, N 7. P. 717724.
35. Kalyani R.R. et al. Hyperglycemia and incidence of frailty and Lower extremity mobility Limitations in older women // J. Am. Geriatr. Soc. 2012. Vol. 60, N 9. P. 1701-1707.
36. Abbatecola A.M. et al. Antidiabetic oral treatment in older people // Drugs Aging. 2009. Vol. 26, N 1. P. 53-62.
37. Mcdermott M.M.G. et al. Impairments of muscLes and nerves associated with peripheraL arteriaL disease and their reLationship with Lower extremity functioning: the InCHIANTI Study // J. Am. Geriatr. Soc. 2004. VoL. 52, N 3. P. 405-410.
38. Cruz-Jentoft A.J.; European Working Group on Sarcopenia in OLder PeopLe: Sarcopenia: European consensus on definition and diagnosis. Report of the European Working Group on Sarcopenia in OLder PeopLe // Age Ageing. 2010. VoL. 39. P. 412-423.
39. Verdijk L.B., GLeeson B.G., Jonkers R.A.M. et aL. SkeLetaL muscLe hypertrophy foLLowing resistance training is accompanied by a fiber type -specific increase in sateLLite ceLL content in eLderLy men // J. GerontoL. A BioL. Sci. Med. Sci. 2009. VoL. 64, N 3. Р. 332-339.
40. NickLas B.J., BrinkLey T.E. Exercise training as a treatment for chronic inflammation in the eLderLy // Exerc. Sport Sci. Rev. 2009. VoL. 37, N 4. P. 165-170.
41. Ogawa K. et aL. Resistance exercise training-induced muscLe hypertrophy was associated with reduction of inflammatory markers in eLderLy women // Mediators InfLamm. 2010. VoL. 2010. ArticLe ID 171023.
42. Kim H.K., Suzuki T., Saito K. et aL. Effects of exercise and amino acid suppLementation on body composition and physicaL function in community-dweLLing eLderLy Japanese sarcopenic women: a randomized controLLed triaL // J. Am. Geriatr. Soc. 2012. VoL. 60. P. 16-23.
43. ZiegLer D. et aL. Efficacy and safety of antioxidant treatment with a-Lipoic acid over 4 years in diabetic poLyneuropathy: the NATHAN 1 triaL // Diabetes Care. 2011. VoL. 34, N 9. P. 2054-2060.
44. Bauer J. et aL. Evidence-based recommendations for optimaL dietary protein intake in oLder peopLe: a position paper from the PROT-AGE Study Group // J. Am. Med. Dir. Assoc. 2013. VoL. 14, N 8. Р. 542-559.
45. Leenders M., van Loon L.J.C. Leucine as a pharmaconutrient to prevent and treat sarcopenia and type 2 diabetes // Nutr. Rev. 2011. VoL. 69, N 11. Р. 675-689.
46. Fitschen P.J. et aL. Efficacy of p-hydroxy-fl-methyLbutyrate suppLementation in eLderLy and cLinicaL popuLations // Nutrition. 2013. VoL. 29, N 1. Р. 29-36.
47. DaLy R.M. Independent and combined effects of exercise and vitamin D on muscLe morphoLogy, function and faLLs in the eLderLy // Nutrients. 2010. VoL. 2, N 9. Р. 1005-1017.
48. Pfeifer M. et aL. Effects of a Long-term vitamin D and caLcium suppLementation on faLLs and parameters of muscLe function in communitydweLLing oLder individuaLs // Osteoporos. Int. 2009. VoL. 20, N 2. P. 315322.
49. Beaudart C. et aL. The effects of vitamin D on skeLetaL muscLe strength, muscLe mass, and muscLe power: a systematic review and metaanaLysis of randomized controLLed triaLs // J. CLin. EndocrinoL. Metab. 2014. VoL. 99, N 11. P. 4336-4345.
50. BisLev L.S. et aL. Effects of vitamin D3 suppLementation on muscLe strength, mass, and physicaL performance in women with vitamin D insufficiency: a randomized pLacebo-controLLed triaL // CaLcif. Tissue Int. 2018. VoL. 103, N 5. P. 483-493.
51. Muir S.W., Montero-Odasso M. Effect of vitamin D suppLementation on muscLe strength, gait and baLance in oLder aduLts: a systematic review and meta-anaLysis // J. Am. Geriatr. Soc. 2011. VoL. 59, N 12. P. 2291-2300.
52. Bhasin S., Woodhouse L., Casaburi R., Singh A.B. et aL. OLder men are as responsive as young men to the anaboLic effects of graded doses of testosterone on the skeLetaL muscLe // J. CLin. EndocrnioL. Metab. 2005. VoL. 90. P. 678-688.
53. SuLLivan D.H. et aL. Effects of muscLe strength training and testosterone in fraiL eLderLy maLes // Med. Sci. Sports Exerc. 2005. VoL. 37, N 10. P. 1664-1672.
54. DaLton J.T. et aL. The seLective androgen receptor moduLator GTx-024 (enobosarm) improves Lean body mass and physicaL function in heaLthy eLderLy men and postmenopausaL women: resuLts of a doubLe-bLind, placebo-controlled phase II trial // J. Cachexia Sarcopenia Muscle. 2011. VoL 2, N 3. P. 153-161.
55. Cohn L., Feller A.G., Draper M.W., Rudman I.W. et al. Carpal tunnel syndrome and gynaecomastia duruing growth hormone treatment of elderly men with low circulating IGF-1 concentrations // Clin. Endocrniol. (Oxf.). 1993. Vol. 39. Р. 417-425.
56. Boonen S. et al. Musculoskeletal effects of the recombinant human IGF-I/IGF binding protein-3 complex in osteoporotic patients with proximal femoral fracture: a double-blind, placebo-controlled pilot study // J. Clin. Endocrinol. Metab. 2002. Vol. 87, N 4. Р. 1593-1599.
57. Rooks D., Praestgaard J., Hariry S., Laurent D. et al. Treatment of sarcopenia with bimagrumab: results from a phase II, randomized, controlled, proof-of-concept study // J. Am. Geriatr. Soc. 2017. Vol. 65, N 9. Р. 1988-1995.
58. Maggio M., Ceda G.P., Lauretani F., Pahor M. et al. Relation of angiotensin converting enzyme inhibitor treatment to insulin-like growth factor-1 serum levels in subjects > 65 years of age (the InCHIANTI study) // Am. J. Cardiol. 2006. Vol. 97. Р. 1525-1529.
59. Bunout D., Barrera G., De La Maza M.P., Leiva L. et al. Effects of enalapril or nifedipine on muscle strength or functional capacity in elderly subjects. A double blind trial // J. Renin Angiotensin Aldosterone Syst. 2009. Vol. 10. Р. 77-84.
60. Campins L., Camps M., Riera A., Pleguezuelos E. et al. Oral drugs related with muscle wasting and sarcopenia. A review // Pharmacology. 2017. Vol. 99, N 1-2. P. 1-8.
61. URL: https://clinicaltrials.gov/ct2/show/NCT02432287. (date of access December 27, 2017)
62. Aranda R., Domenech E., Rus A.D., Real J.T. et al. Age-related increase xanthine oxidase activity in human plasma and rat tissues // Free Radic. Res. 2007. Vol. 41. Р. 1195-1200.
63. Springer J., Tschirner A., Hartman K., Palus S. et al. Inhibition of xanthine oxidase reduces wasting and improves outcome in a rat model of cancer cachexia // Int. J. Cancer. 2012. Vol. 131. Р. 2187-2196.
64. Beveridge L.A., Ramage L., McMurdo M.E., George J., Witham M.D. Allopurinol use is associated with greater functional gains in older rehabilitation patients // Age Ageing. 2013. N 42. Р. 400-404.
65. Busquets S., Figueras M.T., Fuster G., Almendro V. et al. Anticachectic effects of formoterol: a drug for potential treatment of muscle wasting // Cancer Res. 2004. Vol. 64. Р. 6725-6731.
References
1. Dedov I.I., Shestakova M.V., Vikulova O.K., Zheleznyakova A.V., et al. Diabetes mellitus in Russian federation: prevalence, morbidity, mortality, parameters of glycaemic control and structure of glucose lowering therapy according to the federal diabetes register, status 2017. Sakharniy diabet [Diabetes Mellitus]. 2018; 21 (3): 144-59. (in Russian)
2. Dedov I.I., Shestakova M.V., Galstyan G.R. The prevalence of type 2 diabetes mellitus in the adult population of Russia (NATION study). Sakharniy diabet [Diabetes Mellitus]. 2016; 19 (2): 104-12. (in Russian)
3. Cruz-Jentoft A.J., et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2018. Oct 13.
4. Grimby G., Saltin B. The ageing muscle. Clin Physiol. 1983; 3 (3): 209-18.
5. Kamimoto L.A., et al. Surveillance for five health risks among older adults - United States, 1993-1997. MMWR CDC Surveill Summ. 1999; 48 (8): 89-130.
6. Kim T.N., et al. Prevalence and determinant factors of sarcopenia in patients with type 2 diabetes: the Korean Sarcopenic Obesity Study (KSOS). Diabetes Care. 2010; 33 (7): 1497-9.
7. Misnikova I.V., Kovaleva Y.A., Klimina N.A., Polyakova E.Y. Assessment of muscle and fat mass in type 2 diabetes mellitus patients by dualenergy X-ray absorptiometry. Almanakh klinicheskoy meditsini [Almanac of Clinical Medicine]. 2018; 46 (3): 222-32. (in Russian)
8. Gurieva I.V., Onuchina Yu.S., Shchelykalina S.P., Begma I.V. Features of sarcopenia and body composition on the basis of bioimpedance measurements in patients with type 2 diabetes mellitus. Voprosy dietologii [Problems of Dietology]. 2017; 7 (2): 11-9. (in Russian)
9. Morley J.E. Diabetes, sarcopenia, and frailty. Clin Geriatr Med. 2008; 24 (3): 455-69.
10. Roubenoff R. Sarcopenic obesity: the confluence of two epidemics. Obes Res. 2004; 1: 887-8.
11. Misnikova I.V., Kovaleva Yu.A., Klimina N.A. Sarcopenic obesity. Russkiy meditsinskiy zhurnal [Russian Medical Journal]. 2017; 25 (1): 24-9. (in Russian)
12. Baumgartner R.N. Body composition in healthy aging. Ann N Y Acad Sci. 2000; 904 (1): 437-48.
13. Shostak N.A., Muradyanc A.A., Kondrashov A.A. Sarcopenia and overlapping syndromes: their value in clinical practice. Klinitsist [Clinician]. 2016; 10 (3): 10-4. (in Russian)
14. Dalal M., et al. Elevated serum advanced glycation end products and poor grip strength in older community-dwelling women. J Gerontol A Biomed Sci Med Sci. 2009; 64 (1): 132-7.
15. Gurieva I.V., Onuchina Yu.S. Modern approaches to the definition, classification and diagnosis of diabetic polyneuropathy. Pathogenetic aspects of treatment. Consilium Medicum. 2016; 18 (12): 103-9. (in Russian)
16. Casellini C., Vinik A. Clinical manifestations and current treatment options for diabetic neuropathies. Endocr Pract. 2007; 13 (5): 550-66.
17. Tesfaye S., et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010; 33 (10): 2285-93.
18. Vinik A.I., et al. Diabetic neuropathy in older adults. Clin Geriatr Med. 2008; 24 (3): 407-35.
19. Andreassen C.S., Jakobsen J., Andersen H. Muscle weakness: a progressive late complication in diabetic distal symmetric polyneuropathy. Diabetes. 2006; 55 (3): 806-12.
20. Lesnyak O.M. (ed.). Osteoporosis: Guide for doctors. Moscow: GEOTAR-Media, 2016. (in Russian)
21. Bus S.A., et al. Intrinsic muscle atrophy and toe deformity in the diabetic neuropathic foot: a magnetic resonance imaging study. Diabetes Care. 2002; 25 (8): 1444-50.
22. Pflipsen M.C., et al. The prevalence of vitamin B12 deficiency in patients with type 2 diabetes: a cross-sectional study. J Am Board Fam Med. 2009; 22 (5): 528-34.
23. Fujita S., et al. Effect of insulin on human skeletal muscle protein synthesis is modulated by insulin-induced changes in muscle blood flow and amino acid availability. Am J Physiol Endocrinol Metab. 2006; 291 (4): E745-54.
24. Nomura T., et al. Muscle strength is a marker of insulin resistance in patients with type 2 diabetes: a pilot study. Endocr J. 2007; 54 (5): 791-6.
25. Kohn F.M. Testosterone and body functions. Aging Male. 2006; 9 (4): 183-8.
26. Kravchenko I.V., Furalev V.A., Tihonov A.V. Titin, myomesin and myosin-binding protein C activate the synthesis of mechano-growth factor in mouse myoblasts. Sovremennye problemy nauki i obrazovaniya [Modern Problems of Science and Education]. 2012; (6): 9. (in Russian)
27. Undricov I.M., Undricov V.M., Andreev Eh.F. Miostatin - a negative regulator of muscle mass - a revolution or a sensation? Fizkul'tura v pro-fiLaktike, Lechenii i reabiLitatsii [Physical Education in Prevention, Treatment and Rehabilitation]. 2003; (1): 64-9. (in Russian)
28. MorLey J.E., Baumgartner R.N. Cytokine-related aging process. J Gerontol A BioL Sci Med Sci. 2004; 59 (9): 924-9.
29. Cesari M., et aL. Inflammatory markers and physical performance in older persons: the InCHIANTI study. J Gerontol A BioL Sci Med Sci. 2004; 59 (3): M242-8.
30. Pereira R.A. Sarcopenia in chronic kidney disease on conservative therapy: prevalence and association with mortality. NephroL Dial Transplant. 2015; 30 (10): 1718-25.
31. Perry H.M., et aL. LongitudinaL changes in serum 25-hydroxyvi-tamin D in oLder peopLe. MetaboLism. 1999; 48 (8): 1028-32.
32. Bischoff-Ferrari H.A., Borchers M., Gudat F., DurmuLLer U., et aL. Vitamin D receptor expression in human muscLe tissue decreases with age. J Bone Miner Res. 2004; 19: 265-9.
33. BouiLLon R., Bischoff-Ferrari H., WiLLett W. Vitamin D and heaLth: perspectives from mice and man. J Bone Miner Res. 2008; 23 (7): 974-9.
34. De BoLand A.R., BoLand R.L. Non-genomic signaL transduction pathway of vitamin D in muscLe. CeLL SignaL. 1994; 6 (7): 717-24.
35. KaLyani R.R., et aL. HypergLycemia and incidence of fraiLty and Lower extremity mobiLity Limitations in oLder women. J Am Geriatr Soc. 2012; 60 (9): 1701-7.
36. AbbatecoLa A.M., et aL. Antidiabetic oraL treatment in oLder peopLe. Drugs Aging. 2009; 26 (1): 53-62.
37. Mcdermott M.M.G., et aL. Impairments of muscLes and nerves associated with peripheraL arteriaL disease and their reLationship with Lower extremity functioning: the InCHIANTI Study. J Am Geriatr Soc. 2004; 52 (3): 405-10.
38. Cruz-Jentoft A.J.; European Working Group on Sarcopenia in OLder PeopLe: Sarcopenia: European consensus on definition and diagnosis. Report of the European Working Group on Sarcopenia in OLder PeopLe. Age Ageing. 2010; 39: 412-23.
39. Verdijk L.B., GLeeson B.G., Jonkers R.A.M., et aL. SkeLetaL muscLe hypertrophy foLLowing resistance training is accompanied by a fiber type -specific increase in sateLLite cell content in eLderLy men. J GerontoL A BioL Sci Med Sci. 2009; 64 (3): 332-9.
40. NickLas B.J., BrinkLey T.E. Exercise training as a treatment for chronic inflammation in the eLderLy. Exerc Sport Sci Rev. 2009; 37 (4): 165-70.
41. Ogawa K., et aL. Resistance exercise training-induced muscLe hypertrophy was associated with reduction of inflammatory markers in eLderLy women. Mediators InfLamm. 2010; 2010: 171023.
42. Kim H.K., Suzuki T., Saito K., et aL. Effects of exercise and amino acid suppLementation on body composition and physicaL function in community-dweLLing eLderLy Japanese sarcopenic women: a randomized controLLed triaL. J Am Geriatr Soc. 2012; 60: 16-23.
43. ZiegLer D., et aL. Efficacy and safety of antioxidant treatment with a-Lipoic acid over 4 years in diabetic poLyneuropathy: the NATHAN 1 triaL. Diabetes Care. 2011; 34 (9): 2054-60.
44. Bauer J., et aL. Evidence-based recommendations for optimaL dietary protein intake in oLder peopLe: a position paper from the PROT-AGE Study Group. J Am Med Dir Assoc. 2013; 14 (8): 542-59.
45. Leenders M., van Loon L.J.C. Leucine as a pharmaconutrient to prevent and treat sarcopenia and type 2 diabetes. Nutr Rev. 2011; 69 (11): 675-89.
46. Fitschen P.J., et aL. Efficacy of p-hydroxy-fl-methyLbutyrate suppLementation in eLderLy and cLinicaL popuLations. Nutrition. 2013; 29 (1): 29-36.
47. DaLy R.M. Independent and combined effects of exercise and vitamin D on muscLe morphoLogy, function and faLLs in the eLderLy. Nutrients. 2010; 2 (9): 1005-17.
48. Pfeifer M., et aL. Effects of a Long-term vitamin D and caLcium suppLementation on faLLs and parameters of muscLe function in communitydweLLing oLder individual. Osteoporos Int. 2009; 20 (2): 315-22.
49. Beaudart C., et aL. The effects of vitamin D on skeLetaL muscLe strength, muscLe mass, and muscLe power: a systematic review and metaanaLysis of randomized controLLed triaLs. J CLin EndocrinoL Metab. 2014; 99 (11): 4336-45.
50. BisLev L.S., et aL. Effects of vitamin D3 suppLementation on muscLe strength, mass, and physicaL performance in women with vitamin D insufficiency: a randomized pLacebo-controLLed triaL. CaLcif Tissue Int. 2018; 103 (5): 483-93.
51. Muir S.W., Montero-Odasso M. Effect of vitamin D suppLementation on muscLe strength, gait and baLance in oLder aduLts: a systematic review and meta-anaLysis. J Am Geriatr Soc. 2011; 59 (12): 2291-300.
52. Bhasin S., Woodhouse L., Casaburi R., Singh A.B., et aL. OLder men are as responsive as young men to the anaboLic effects of graded doses of testosterone on the skeLetaL muscLe. J CLin EndocrnioL Metab. 2005; 90: 678-88.
53. SuLLivan D.H., et aL. Effects of muscLe strength training and testosterone in fraiL eLderLy maLes. Med Sci Sports Exerc. 2005; 37 (10): 1664-72.
54. DaLton J.T., et aL. The seLective androgen receptor moduLator GTx-024 (enobosarm) improves Lean body mass and physicaL function in heaLthy eLderLy men and postmenopausaL women: resuLts of a doubLe-bLind, pLacebo-controLLed phase II triaL. J Cachexia Sarcopenia MuscLe. 2011; 2 (3): 153-61.
55. Cohn L., FeLLer A.G., Draper M.W., Rudman I.W., et aL. CarpaL tunneL syndrome and gynaecomastia duruing growth hormone treatment of eLderLy men with Low circuLating IGF-1 concentrations. CLin EndocrnioL (Oxf). 1993; 39: 417-25.
56. Boonen S., et aL. MuscuLoskeLetaL effects of the recombinant human IGF-I/IGF binding protein-3 compLex in osteoporotic patients with proximaL femoraL fracture: a doubLe-bLind, pLacebo-controLLed piLot study. J CLin EndocrinoL Metab. 2002; 87 (4): 1593-9.
57. Rooks D., Praestgaard J., Hariry S., Laurent D., et aL. Treatment of sarcopenia with bimagrumab: resuLts from a phase II, randomized, controLLed, proof-of-concept study. J Am Geriatr Soc. 2017; 65 (9): 1988-95.
58. Maggio M., Ceda G.P., Lauretani F., Pahor M., et aL. ReLation of angiotensin converting enzyme inhibitor treatment to insuLin-Like growth factor-1 serum LeveLs in subjects > 65 years of age (the InCHIANTI study). Am J CardioL. 2006; 97: 1525-9.
59. Bunout D., Barrera G., De La Maza M.P., Leiva L., et aL. Effects of enaLapriL or nifedipine on muscLe strength or functionaL capacity in eLderLy subjects. A doubLe bLind triaL. J Renin Angiotensin ALdosterone Syst. 2009; 10: 77-84.
60. Campins L., Camps M., Riera A., PLeguezueLos E., et aL. OraL drugs reLated with muscLe wasting and sarcopenia. A review. PharmacoLogy. 2017; 99 (1-2): 1-8.
61. URL: https://clinicaltrials.gov/ct2/show/NCT02432287. (date of access December 27, 2017)
62. Aranda R., Domenech E., Rus A.D., ReaL J.T., et aL. Age-reLated increase xanthine oxidase activity in human pLasma and rat tissues. Free Radic Res. 2007; 41: 1195-200.
63. Springer J., Tschirner A., Hartman K., PaLus S., et aL. Inhibition of xanthine oxidase reduces wasting and improves outcome in a rat modeL of cancer cachexia. Int J Cancer. 2012; 131: 2187-96.
64. Beveridge L.A., Ramage L., McMurdo M.E., George J., Witham M.D. ALLopurinoL use is associated with greater functionaL gains in oLder rehabiLitation patients. Age Ageing. 2013; (42): 400-4.
65. Busquets S., Figueras M.T., Fuster G., ALmendro V., et aL. Anticachectic effects of formoteroL: a drug for potentiaL treatment of muscLe wasting. Cancer Res. 2004; 64: 6725-31.